ArticleMolecular biotechnology2026
Anti-chikungunya Activity of a Cinnamic Acid Derivative: An In Vitro and In Silico Study.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent progress in anti-Chikungunya virus drug discovery: Focus on the viral life cycle and direct-acting antivirals.Virologica Sinica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) is an arthropod-borne virus that causes debilitating joint pain and fever with limited treatment options. Cinnamic acid, known for its broad-spectrum biological activities, and its derivatives were evaluated for their potential antiviral effects against CHIKV. In vitro experiments assessed the cytotoxicity of cinnamic acid and its derivatives and their efficacy in inhibiting CHIKV under different treatment settings. Additionally, molecular docking of the effective compounds with CHIKV proteins was performed to determine the probable targets. The results indicated that the derivative CATD-3, a 3,6-(substituted phenyl)-(1,2,4) triazolo [3,4-b][1,3,4] thiadiazole compound, showed antiviral activity under post-infection treatment conditions in Vero CCL-81 cells. The dose-dependent studies revealed that the 50% inhibitory concentration (IC50) was 11.49 µM and the selectivity index of CATD-3 was 13.39. The antiviral activity of CATD-3 was also observed in HeLa cells. In-silico studies revealed that the CATD-3 binds multiple non-structural proteins (nsP) i.e., nsP1, nsP2, and nsP4 of the virus with good binding energies and forming strong interactions with conserved residues on nsP1 methyl transferase (Val 129, Tyr 130, Ala 131) and nsP2 helicase (Met 91, Met 289, and Thr 261) and critical residues of the nsP4 RdRp (Arg331 and Asp 350). The combined in vitro and in silico studies underscores the therapeutic potential of cinnamic acid derivative, CATD-3, as a promising antiviral candidate against CHIKV.
Indexed as
Identifiers
40742524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.